Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

226,531-226,560 of 319,975

filter-aware
03
The slide uses a 2x2 grid layout to summarize key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
04
The slide uses a list of four key pillars of the company's methodology.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
06
The slide uses a timeline to connect corporate strategy to specific clinical trial milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
07
The slide features a split layout with a left-hand column for advisors/board and a right-hand grid for the leadership team, plus a footer highlighting 12 prior FDA approvals.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a Gantt-style visualization to represent drug development stages.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
12
Slide 12 of a pitch deck, likely from Nuvalent.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
13
The slide uses a timeline-based journey map to contrast standard treatments with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
15
The slide presents two distinct scientific data sets: an IC50 dot plot for in vitro activity and a bar chart for in vivo tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI therapies.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
21
Clinical trial data (ALKove-1) showing efficacy of NVL-655 in NSCLC patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Swimmer plot visualization of clinical trial patient outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Includes before/after MRI scans for two specific patient cases.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
Data cut-off: 8 Aug 2023. N=93 treated patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial design with specific patient cohorts (2a-2d) and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key program attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a timeline-based framework to contrast 1L and 2L+ treatment landscapes and their associated clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
Includes specific pharmacological data points for NVL-520 vs competitors like Crizotinib, Entrectinib, Lorlatinib, Taletrectinib, and Repotrectinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Data presented in two side-by-side tables summarizing patient characteristics and treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit